Efficacy of different concentrations of ZKY001 eyedrops in the treatment of corneal epithelial defect after primary pterygium excision
- VernacularTitle:不同浓度ZKY001滴眼液治疗原发性翼状胬肉切除术后角膜上皮缺损的疗效
- Author:
Hua GAO
1
,
2
,
3
,
4
,
5
;
Lei ZHU
1
,
2
,
3
,
4
,
5
;
Jianjiang XU
1
,
2
,
3
,
4
,
5
;
Liming TAO
1
,
2
,
3
,
4
,
5
;
Yanling DONG
1
,
2
,
3
,
4
,
5
;
Luxia CHEN
1
,
2
,
3
,
4
,
5
;
Xiuming JIN
1
,
2
,
3
,
4
,
5
;
Guigang LI
1
,
2
,
3
,
4
,
5
;
Huping WU
1
,
2
,
3
,
4
,
5
;
Ping ZHAO
1
,
2
,
3
,
4
,
5
;
Wei CHEN
1
,
2
,
3
,
4
,
5
;
Xiaoyi LI
1
,
2
,
3
,
4
,
5
;
Weiyun SHI
1
,
2
,
3
,
4
,
5
Author Information
- Publication Type:Journal Article
- Keywords: pterygium excision; ZKY001 eyedrops; corneal epithelial defect repair; relieve discomfort; efficacy and safety
- From: International Eye Science 2024;24(12):1888-1894
- CountryChina
- Language:Chinese
- Abstract: AIM: To investigate the efficacy and safety of ZKY001 eye drops with different concentrations in the treatment of corneal epithelial defects(CED)after primary pterygium excision.METHODS: This was a multicenter, randomized, double-blinded, placebo-controlled phase II clinical trial. From March 15, 2022 to November 14, 2022, patients with primary pterygium who had undergone surgery were recruited from 12 tertiary hospitals across China. Using block randomization, 178 patients(178 eyes)were randomly assigned to 3 groups in a 1:1:1 ratio: 0.002% ZKY001 group(n=59), 0.004% ZKY001 group(n=59), and placebo group(n=60, receiving ZKY001 sham eye drops). Subjects in each group received 1 drop of the study drug 4 times per day for 4 d. The percentage of CED area recovery from baseline, the first complete healing time of CED area, the number of first complete healing cases of CED, and changes in visual analogue scale(VAS)scores for eye discomfort including eye pain, foreign body sensation, tearing and photophobia were observed.RESULTS: In terms of improvement in CED, there were no statistically significant differences among the three groups including the first healing time of CED, the percentage improvement in CED area compared to baseline, and the percentage of first healing cases at different follow-up visits(all P>0.05). Numerically, the first healing time of CED was shorter in the test groups compared to the placebo group(67.87±21.688 h for the 0.002% ZKY001 group, 61.48±22.091 h for the 0.004% ZKY001 group, and 68.85±20.851 h for the placebo group). On D1 morning, the percentage improvement in CED area compared to baseline was maximally different from the placebo group, and the numerical difference advantage was maintained at subsequent follow-up visits. The number of first healing cases in the CED area at different follow-up visits was higher in the test groups than the placebo group. In terms of improvement in ocular discomfort, the total VAS scores were lower in the test groups compared to the placebo group, mainly due to reductions in foreign body sensation and pain scores. At D3, the 0.004% ZKY001 group showed statistically significant improvement in foreign body sensation(P<0.017). In terms of safety, the overall incidence of adverse events was low(9.0%)and similar among groups.CONCLUSION: The use of ZKY001 eyedrops after primary pterygium surgery can safely improve the CED repair, and alleviate postoperative symptoms caused by CED.
